Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) has entered into a technology development contract with its wholly-owned subsidiary Jiangsu Corning Jereh Biopharmaceutical Co., Ltd. and Suzhou Corning Jereh Biotechnology Co., Ltd. to enhance its development of bispecific antibody-drug conjugates (ADCs) [1] Group 1 - The contract, signed on August 8, 2025, involves Suzhou Corning Jereh providing technical development services, including the development of production processes and analytical methods for ADC candidates [1] - Suzhou Corning Jereh has been a reliable service provider since 2018, possessing extensive experience and competitiveness in process optimization services [1] - The company believes that the contract will help optimize existing production and R&D processes, reduce related costs, and positively impact future product development, manufacturing, and IND applications [1]
康宁杰瑞制药-B(09966)与苏州康宁杰瑞订立一份技术开发合同